Sentiment Trading

Absci Corporation, a synthetic biology company, reported Q2 2025 financials with a slight improvement in quarterly loss per share and a 4.72% reduction in revenue, but analysts remain optimistic about its potential for growth and innovation.

AbSci Corporation is a pioneering synthetic biology company revolutionizing biologic drug discovery and development with its integrated platform, aiming to transform the healthcare sector.

Absci Corporation has announced a milestone in its clinical trial of ABS-101, a potential treatment for Inflammatory Bowel Disease, and reported stronger-than-expected financial performance for Q1 2025.